Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of January 2012. The document serves as a Change of Director's Interest Notice filed with the Australian Securities Exchange (ASX) and furnished to the SEC. The registrant is a foreign private issuer based in Parkville, Victoria, Australia.
Key Financial Metrics
The filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a regulatory disclosure regarding a specific transaction by a director.
Material Changes
The primary material change disclosed is an increase in the shareholding of Director Geoffrey Kempler:
- Date of Change: January 4, 2012
- Transaction Type: On-market acquisition
- Shares Acquired: 600,000 Fully Paid Ordinary shares
- Consideration: $104,564
- Holdings Prior to Change: 17,055,000 total shares (30,000 direct; 17,025,000 indirect)
- Holdings After Change: 17,655,000 total shares (30,000 direct; 17,625,000 indirect)
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was not conducted during a closed period, and no prior written clearance was required.
Investor Verification Checklist
- Verify the current market price of Prana Biotechnology Limited (ASX:PBT) shares to contextualize the $104,564 acquisition value.
- Confirm the total number of issued shares outstanding to calculate the director's updated percentage ownership.
- Review recent ASX announcements for any other director or substantial shareholder trading activity.
- Check the company's latest Form 20-F or annual report for financial performance data, as this 6-K does not provide it.